Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhep.2007.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial.
Medicine (Baltimore)
November 2024
Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia.
Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with liver inflammation, fibrosis, and cirrhosis and is associated with a greater risk of hepatocarcinoma. Nonalcoholic steatohepatitis (NASH) is a persistent and progressive form of NAFLD. Recent evidence suggested that ertugliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2), suppresses NAFLD development in patients with type 2 diabetes mellitus (T2DM).
View Article and Find Full Text PDFBenefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study.
Diabetes Obes Metab
February 2025
Division of Endocrinology and Metabolism, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Article Synopsis
- The study investigates the effects of combining pioglitazone, GLP1RA, and SGLT2i on metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes.
- Results from 888 patients showed that using more of these medications correlated with significant improvements in liver health, as measured by changes in the FAST score over a median follow-up of 3.9 years.
- Specifically, the combination of SGLT2i and pioglitazone was associated with the highest likelihood of achieving better FAST score outcomes, suggesting a promising approach for managing MASH in diabetic patients.
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
J Clin Transl Hepatol
September 2024
Department of Gastroenterology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- There is a growing global concern over metabolic dysfunction-associated steatotic liver disease (MASLD), yet no licensed medications exist for its treatment.
- Recent research has illuminated the complex nature of MASLD, paving the way for the development of new drugs and repurposing existing ones.
- Treatment strategies focus on four key pathways: antidiabetic medications, managing hepatic lipid accumulation, addressing oxidative stress/inflammation, and targeting gut health, with combination therapies seen as a promising approach for improved effectiveness and reduced side effects.
Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.
Pharmaceuticals (Basel)
June 2024
Phytomedicine, Biochemical Toxicology and Biotechnology Research Laboratories, Department of Biochemistry, College of Sciences, Afe Babalola University, Ado-Ekiti 360001, Nigeria.
Article Synopsis
- There is currently no cure for diabetes, particularly type 2 diabetes mellitus (T2DM), but various pharmaceutical therapies are available for its management, categorized by their mechanisms of action.
- While some medications show effectiveness, they come with significant side effects from prolonged use.
- Phytochemicals found in medicinal plants are emerging as promising candidates for new treatments, as they can activate the glucagon-like peptide-1 receptor (GLP-1R) similarly to existing agonists, potentially offering a more affordable and safer alternative for T2DM management.
Organokines and liver enzymes in adolescent girls with polycystic ovary syndrome during randomized treatments.
Front Endocrinol (Lausanne)
May 2024
Endocrinology Department, Institut de Recerca Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Introduction: Polycystic ovary syndrome (PCOS) is often associated with metabolic-associated fatty liver disease (MAFLD). MAFLD has been associated with altered hepatic function, systemic dysmetabolism, and abnormal circulating levels of signaling molecules called organokines. Here, we assessed the effects of two randomized treatments on a set of organokines in adolescent girls with PCOS and without obesity, and report the associations with circulating biomarkers of liver damage, which were assessed longitudinally in the aforementioned studies as safety markers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!